Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).
about
Immunology of hepatocellular carcinomaInhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinomaIL-7 in human health and disease.Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma.Serum levels of soluble CD25 as a marker for hepatocellular carcinomaRole of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review)Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.Growth of HepG2 cells was suppressed through modulation of STAT6/IL-4 and IL-10 in RAW 264.7 cells treated by phytoglycoprotein (38 kDa).Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.Another armed CD4(+) T cell ready to battle hepatocellular carcinoma.Early heme oxygenase 1 induction delays tumour initiation and enhances DNA damage repair in liver macrophages of Mdr2 mice
P2860
Q26795411-6D57FF97-DD61-4CE6-93A4-5A2A86E7EF24Q28567794-7530E30B-53F8-423C-8AA1-1BCE5AA50584Q34260682-DE0C72FD-1B2D-406F-97AE-1AB0249DBCE1Q34277756-116F6185-EA2F-4F7C-91D2-86C2CADA4909Q34645945-97CB916E-246D-4EBA-BC08-1B92B63CBDC4Q34993924-E7785292-3AF2-4FAB-97F9-6C34D6812216Q36835490-5B7B49A0-308D-4DB1-93F4-D6885CC0E280Q37393627-82232482-38F0-4075-B77F-688354800652Q39237992-47EA2485-4183-4F61-BB74-5FAF30E02ACCQ39592084-B1897A35-0D44-41C8-A51E-94FCB610EE1CQ42112406-BDAE5B1D-CD15-4555-AF32-91F75C3F9042Q45796005-4A64CEE6-C9EC-44AE-847A-F22B838F4584Q58618219-617594B5-436C-423F-B2C7-5DBF5669104F
P2860
Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25).
@ast
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25).
@en
type
label
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25).
@ast
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25).
@en
prefLabel
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25).
@ast
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25).
@en
P2093
P2860
P1476
Hepatocellular carcinoma immun ...... role for soluble CD25 (sCD25)
@en
P2093
David R Nelson
Mark A Atkinson
Mengde Cao
Miguel Ararat
Roniel Cabrera
P2860
P2888
P304
P356
10.1007/S10620-009-0955-5
P577
2010-02-01T00:00:00Z